---
document_datetime: 2023-09-21 17:23:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/visudyne-epar-procedural-steps-taken-authorisation_en.pdf
document_name: visudyne-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4241004
conversion_datetime: 2025-12-19 01:29:55.478119
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## I. BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant CibaVision Europe Ltd. submitted on 6 August 1999 an application for Marketing Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for Visudyne, through the centralised procedure. After agreement by the CPMP on 25 March 1999, this  medicinal  product  was  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No  (EC) 2309/93 of 22 July 1993, as amended.

The Rapporteur and Co-Rapporteur appointed by the CPMP and the evaluation teams were:

Rapporteur:

Dr E Abadie

Co-Rapporteur:

Dr M Ainsworth (replacing Dr G Jensen )

## Licensing status :

The product was not licensed in any country inside or outside the EU at the time of submission of the application. An NDA application was submitted to the FDA on 16 August 1999, 10 days after the EU submission.

## 2. Steps taken for the assessment of the product

- The applicant's dossier was received on 6 August 1999.
- The procedure started on 27 August 1999.
- The  Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  members  on  5 November 1999.
- The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on 8 November 1999.
- During the meeting on 14 - 16 December 1999 the CPMP agreed on the consolidated list of questions to be sent to the company. The final consolidated List of Questions was sent to the applicant on 17 December 1999.
- The applicant  met  with  the  Rapporteur  and  Co-Rapporteur  at  the  EMEA  on  17  January 2000 in order to clarify certain clinical and pharmaceutical issues in the List of Questions.
- The responses to the List of Questions were submitted on 1 February 2000.
- The  Rapporteur  circulated  the  Rapporteur/Co-Rapporteur  joint  assessment  report  on  the company's responses to the List of Questions to all CPMP Members on 23 March 2000.
- The applicant submitted a revised SPC on 8 April 2000
- During  the  meeting  on  11  -  13  April  2000  the  CPMP,  in  the  light  of  the  overall  data submitted and the scientific discussion within the Committee issued a positive opinion by consensus  for  granting  a  Marketing  Authorisation  for  the  product  Visudyne  on  12  April 2000. The Norwegian and Icelandic CPMP Members agreed with this opinion.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 27 July 2000.